RightFit Trial Directory

Breast Cancer clinical trials in Palo Alto, CA

14 recruiting breast cancer studies with a site in Palo Alto, CA.

All trials in Palo Alto, CA · All Breast Cancer trials

RecruitingPhase 3NCT07391774

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Sponsor: National Cancer Institute (NCI)

Auburn, CA · Berkeley, CA · Beverly Hills, CA · +200 more sites

RecruitingPhase not listedNCT07616856

Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry

Sponsor: Lumicell, Inc.

Palo Alto, CA

RecruitingPhase 3NCT07174336

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Sponsor: Eli Lilly and Company

Clovis, CA · Duarte, CA · Emeryville, CA · +126 more sites

RecruitingPhase 3NCT06790693

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Sponsor: Hoffmann-La Roche

Burbank, CA · Irvine, CA · La Jolla, CA · +59 more sites

RecruitingPhase 2NCT07405801

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Sponsor: Hoffmann-La Roche

Anaheim, CA · Palo Alto, CA · +8 more sites

RecruitingPhase 1NCT06840886

A Study of PHST001 in Advanced Solid Tumors

Sponsor: Pheast Therapeutics

Beverly Hills, CA · Los Angeles, CA · Palo Alto, CA · +17 more sites

RecruitingPhase 3NCT06982521

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Sponsor: Relay Therapeutics, Inc.

Beverly Hills, CA · Duarte, CA · Los Angeles, CA · +49 more sites

RecruitingPhase 3NCT06492616

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Sponsor: Stemline Therapeutics, Inc.

Bakersfield, CA · Berkeley, CA · Beverly Hills, CA · +173 more sites

RecruitingPhase 3NCT05879926

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Sponsor: NRG Oncology

Anaheim, CA · Antioch, CA · Arroyo Grande, CA · +1223 more sites

RecruitingPhase 3NCT05232916

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Sponsor: Greenwich LifeSciences, Inc.

Duarte, CA · Fullerton, CA · Irvine, CA · +48 more sites

RecruitingPhase 3NCT05812807

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Sponsor: Alliance for Clinical Trials in Oncology

Arroyo Grande, CA · Berkeley, CA · +825 more sites

RecruitingPhase 1NCT06562192

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Sponsor: Novartis Pharmaceuticals

Los Angeles, CA · Palo Alto, CA · +7 more sites

RecruitingPhase 3NCT04852887

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Sponsor: NRG Oncology

Anaheim, CA · Antioch, CA · Arroyo Grande, CA · +809 more sites

RecruitingPhase 3NCT05929768

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Sponsor: SWOG Cancer Research Network

Anaheim, CA · Arroyo Grande, CA · +952 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.